English eShop Sign in (0 Items) €0.00 Nine-Month Results of Sartorius Stedim Biotech Learn More News & Publications Presentations Regulated Information Share Financial Calendar Shareholders' Meeting Homepage Company Investor Relations Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech S.A. Investor Relations A Trusted Partner for the Biopharmaceutical Industry and Laboratories Sartorius Stedim Biotech is a leading international partner for the biopharma sector. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. Seven reasons to invest Clear focus on the attractive biopharma sector Long-term growth drivers and significant market entrance barriers Market leading position in key technologies and recognized brand High share of recurring revenue as well as diversified earnings base Strong presence in growth regions Proven track record with alliances and acquisitions High continuity with respect to customer base, employees and management Sartorius Stedim Biotech | 9M 2021 Results Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent Dynamic and profitable organic growth; significant demand momentum generated by the production of coronavirus vaccines as well as strong development of acquisitions Forecast raised at the beginning of July for 2021 confirmed Earnings Release Conference Call Presentation Conference Call Audio Documents Investors Presentation 9M 2021 Results PDF 3.1 MB Download About Sartorius Stedim Biotech Learn More Strategy and Targets for 2025 Sartorius Stedim Biotech’s goal is to continue its profitable growth and systematically expand its position as a leading international partner for biopharmaceutical research and the industry. We are pursuing various strategic initiatives to grow sustainably up to 2025 – and beyond. Financial Targets for 2025 Focus on the High-Growth Biopharma Market Development of the Product Portfolio Expansion of Our Global Presence and Infrastructure Outlook for 2021 Corporate Structure Downloads Nine-Month Results January to September 2021 October 20, 2021 Earnings Release 9M|2021 PDF | 200.5 KB Financial Data 9M|2021 XLSX | 63.9 KB Conference Call 9M|2021 Presentation PDF | 388.4 KB Conference Call 9M|2021 Audio MPEG | 18.2 MB Half-Year 2021 Results July 21, 2021 Half-Year Report H1|2021 PDF | 1015.8 KB Financial Data H1|2021 XLSX | 70.3 KB Conference Call H1|2021 Presentation PDF | 670.7 KB Conference Call H1|2021 Audio MPEG | 12.6 MB Press Release H1|2021 PDF | 90.8 KB Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021 Online Half-Year Report First-Quarter Results January to March 2021 April 21, 2021 Earnings Release Q1|2021 PDF | 196.0 KB Financial Data Q1|2021 XLSX | 96.0 KB Conference Call Q1|2021 Presentation PDF | 447.3 KB Conference Call Q1|2021 Audio | 10.7 MB Sartorius Stedim Biotech increases its full-year 2021 guidance Financial Publications Learn More Get in Touch Petra Kirchhoff Head of Corporate Communications & Investor Relations p: +49 551 308 1686 Send Email Financial Calendar 06 Dec 21 Conference/Roadshow Berenberg Virtual European Conference 23 Dec 21 Financial Publication Start of Reporting Period Q4/FY Financial Calendar Learn More Top News Sartorius Stedim Biotech Nine-month results of Sartorius Stedim Biotech Read More More Information Newsroom Learn More Facts & Figures Learn More Investor Relations Sartorius AG Learn More Sign Up for Newsletter General Information Imprint Disclaimer Terms & Conditions Legal Documents Patents and Trademarks Data Protection Cookie Policy Declaration of Consent Company About Sartorius Career Investor Relations Newsroom Sartorius Blogs Exhibition | Conferences Contact © 2021 Sartorius AG